CLIA Kit for Galectin 9 (GAL9) Mus musculus (Mouse) Sandwich CLIA

LGALS9; Ecalectin; Lectin,Galactoside-Binding Soluble 9; Tumor antigen HOM-HD-21

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Galectin 9 (GAL9) Packages (Simulation)
  • CLIA Kit for Galectin 9 (GAL9) Packages (Simulation)
  • CLIA Kit for Galectin 9 (GAL9) Results demonstration
  • SCA309Mu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Galectin 9 (GAL9) and the recovery rates were calculated by comparing the measured value to the expected amount of Galectin 9 (GAL9) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 96-104 101
EDTA plasma(n=5) 94-102 97
heparin plasma(n=5) 98-105 101

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Galectin 9 (GAL9) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Galectin 9 (GAL9) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Galectin 9 (GAL9) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 96-104% 99-105% 94-101% 88-98%
EDTA plasma(n=5) 87-99% 98-105% 93-102% 98-105%
heparin plasma(n=5) 81-101% 97-105% 81-96% 85-102%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Galectin 9 (GAL9)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Galectin 9 (GAL9). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Galectin 9 (GAL9). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Galectin 9 (GAL9) level in the sample or standard.;

Citations

  • Temporal Increases in Urinary Carboxymethyllysine Correlate with Albuminuria Development in DiabetesKarger: 328581
  • Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cellsScienceDirect: S1521661611001057
  • Rat Renal Interstitial Fibroblasts Affect the Th1/Th2 Profile In VitroPubmed: 22013937
  • Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney diseasePubMed: 23339460
  • Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infectionPubMed: PMC3750478
  • Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus InfectionPubMed: PMC3480425
  • Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis CPubMed: PMC3688567
  • Graves’ Disease Is Associated with a Defective Expression of the Immune Regulatory Molecule Galectin-9 in Antigen-Presenting Dendritic CellsPubMed: 25880730
  • Molecules of Damage-Associated Patterns in Bronchoalveolar Lavage Fluid and Serum in Chronic Obstructive Pulmonary DiseasePubmed:29429028
  • Galectin-9-like from Angiostrongylus cantonensis young adult worms modulates eosinophil chemotaxis in vitroDoi: 10.1016/j.jmii.2018.09.010
  • The effects of Tim‑3 activation on T‑cells in gastric cancer progression
  • Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra …Pubmed: 31337865
  • Blood Levels of Galectin-9, an Immuno-Regulating Molecule, Reflects the Severity for the Acute and Chronic Infectious Diseases. Biomolecules 2021, 11, 43033804076
  • Regulatory T cells, damage-associated molecular patterns, and myeloid-derived suppressor cells in bronchoalveolar lavage fluid interlinked with chronic obstructive …Pubmed:35687771

Recommend products